Lee Rosen, MD
Hematology-Oncology · Santa Monica, CANPI 1346295870
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Pfizer accounts for 84.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $462 and has fallen 94.3% since, to $26 in 2025. That places this record below the midpoint for hematology-oncology clinicians in CA, where the typical reported total is $1,839.
Across 7 payments — averaging $83.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$494
- Takeda Pharmaceuticals U.S.A., Inc.$66
- AbbVie$26
Across 337 payments — averaging $8053.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.1M
- Taiho Oncology, Inc.$627K
- Beigene AUS Pty Ltd$252K
- Bayer$238K
- Deciphera Pharmaceuticals Inc.$147K
- Astrazeneca UK Limited$96K
- plus $261K from 7 others
What the payments were for
- Speaking & faculty fees$33056%
- Food & beverage$14425%
- Education$11119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| AbbVie | 1 | $26 |
How this compares
$585 in reported general payments places this provider in the 45th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 18 | $329,231 |
| BraftoviEncorafenib | 11 | $141,448 |
| Pantoprazole Sodium | 14 | $220 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Santa Monica
- Sant ChawlaSanta Monica$33K
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.